AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X
[{"orgOrder":0,"company":"MRM Health","sponsor":"International Flavors and Fragrances","pharmaFlowCategory":"D","amount":"$15.1 million","upfrontCash":"Undisclosed","newsHeadline":"DuPont Nutrition & Biosciences Enters into Collaboration","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"MRM Health"},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"JDRF T1D","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Repertoire Immune Medicines Launches Type 1 Diabetes Focused Program with Investment from JDRF T1D Fund","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Repertoire Immune Medicines"},{"orgOrder":0,"company":"Evotec","sponsor":"Ildong Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec and Ildong to collaborate with development projects on INDiGO platform","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Evotec"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Sernova","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AgeX Therapeutics and Sernova to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"AgeX Therapeutics"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MiNA Therapeutics Announces Research Collaboration with AstraZeneca in Metabolic Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Mina Therapeutics"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$7.0 million","newsHeadline":"REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV\u00ae Technology Platform","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Regenxbio"},{"orgOrder":0,"company":"Kriya Therapeutics","sponsor":"QVT","pharmaFlowCategory":"D","amount":"$80.5 million","upfrontCash":"Undisclosed","newsHeadline":"Kriya Therapeutics announces $80 million Series A financing to advance gene therapies for highly prevalent serious diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Kriya Therapeutics"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lannett Provides Update On Clinical Advancement Of Biosimilar Insulin Glargine, Following FDA Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Lannett Company, Inc."},{"orgOrder":0,"company":"Adalvo","sponsor":"AmbioPharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adalvo and AmbioPharm Partner on Development & Licensing for Key Peptide Product","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Peptide","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Adalvo"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chugai Enters into a License Agreement for Chugai\u2019s Antibody Engineering Technologies with Novo Nordisk","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"JAPAN","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Chugai Pharmaceutical"},{"orgOrder":0,"company":"Zucara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Zucara Therapeutics"},{"orgOrder":0,"company":"HEC Group","sponsor":"Lannett","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lannett Expands Strategic Relationship To Include Biosimilar Fast-Acting Insulin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Peptide","productStatus":"Biosimilar","date":"February 2021","url1":"","url2":"","graph1":"Peptide","graph2":"HEC Group"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Crossject","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"CROSSJECT: License agreement in the United States and Canada with Eton Pharmaceuticals for ZENEO\u00ae Hydrocortisone","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Eton Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Soliqua\u00ae Data Shows Improved Blood Sugar Control Without Weight Gain Versus Premixed Insulin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Peptide","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Sanofi"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xeris Pharmaceuticals Enters Collaboration Agreement with Merck","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Xeris Pharmaceuticals"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Massachusetts Institute of Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk Expands Research Collaboration in Novel Delivery Technologies for Biologic Medicines","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Novo Nordisk"},{"orgOrder":0,"company":"Biocon","sponsor":"Zentiva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocon Limited Enters Into a Commercialization Agreement With Zentiva in Europe","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"INDIA","productType":"Peptide","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Biocon"},{"orgOrder":0,"company":"Ypsomed","sponsor":"Civica Rx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Peptide","productStatus":"Biosimilar","date":"January 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Ypsomed"},{"orgOrder":0,"company":"Tulex Pharmaceutical","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Tulex Pharmaceutical"},{"orgOrder":0,"company":"Civica Rx","sponsor":"CalRx Biosimilar Insulin Initiative","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"California Selects Civica Rx as Its Insulin Manufacturing Partner","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Peptide","productStatus":"Biosimilar","date":"March 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Civica Rx"},{"orgOrder":0,"company":"Diabeloop","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Diabeloop Announces Collaboration With Novo Nordisk to Pursue Its Interoperability Strategy With Connected Insulin Pens","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Peptide","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Diabeloop"},{"orgOrder":0,"company":"Aspect Biosystems","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$2,675.0 million","upfrontCash":"$75.0 million","newsHeadline":"Aspect Biosystems And Novo Nordisk Enter Partnership To Develop Bioprinted Tissue Therapeutics For Diabetes And Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Aspect Biosystems"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$2,085.0 million","upfrontCash":"$85.0 million","newsHeadline":"Astra Zeneca Announces Agreement with Quell Therapeutics to Develop, Manufacture and Commercialise Engineered T-Regulatory Cell Therapies for Autoimmune Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Quell Therapeutics"},{"orgOrder":0,"company":"KayoThera","sponsor":"NIH NIDDK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KayoThera, Inc. Strengthens Financial Position with $5.2 Million in Grant and Expanded Series A Funding, Bringing Total Financial Support to $14 Million","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"KayoThera"}]

Find Novel Endocrinology Drugs in Clinical Development

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            Participants were randomized to switch from their prior insulin to either Soliqua once daily or premixed insulin twice daily, with starting doses determined and adjusted weekly. Any metformin or SGLT-2i treatment was maintained through the study period.

            Lead Product(s): Insulin Glargine,Lixisenatide

            Therapeutic Area: Endocrinology Product Name: Soliqua

            Highest Development Status: Undisclosed Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 28, 2021

            Sanofi Company Banner

            AMWC Asia-TDAC

            Not Confirmed

            envelop Contact Supplier

            Details:

            The net funding will support the advancement of KayoThera’s pipeline of first-in-class antagonists of the retinoid pathway as novel oral therapies for Type 2 Diabetes.

            Lead Product(s): Undisclosed

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: NIH NIDDK

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding July 19, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The collaboration aims to focus on the type 1 diabetes and inflammatory bowel disease using Quell’s proprietary toolbox of Treg cell engineering modules, including its innovative Foxp3 Phenotype Lock, to develop autologous multi-modular Treg cell therapy candidates.

            Lead Product(s): Treg-based Cell Therapy

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: AstraZeneca

            Deal Size: $2,085.0 million Upfront Cash: $85.0 million

            Deal Type: Collaboration June 09, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, Novo Nordisk will receive an exclusive, worldwide licence to use Aspect’s bioprinting technology to develop bioprinted tissue therapeutics including up to four products for the treatment of diabetes and obesity.

            Lead Product(s): Bioprinted-based Tissue Therapy

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Novo Nordisk

            Deal Size: $2,675.0 million Upfront Cash: $75.0 million

            Deal Type: Collaboration April 12, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The collaboration will focus on the integration of Novo Nordisk's new generation of connected pens, NovoPen® 6 and NovoPen Echo® Plus with DBL-4pen™. Diabeloop is planning a study for Type 2 diabetes to evaluate the efficacy and clinical benefits of the combined technologies.

            Lead Product(s): Insulin

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Peptide

            Partner/Sponsor/Collaborator: Novo Nordisk

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 21, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Californians with diabetes will have access to Civica’s low-cost insulins via the CalRx Biosimilar Insulin Initiative. Civica will produce three insulins, glargine, lispro and aspart, available both in vials and prefilled pens under the CalRx label.

            Lead Product(s): Insulin

            Therapeutic Area: Endocrinology Product Name: Undislcosed

            Highest Development Status: Undisclosed Product Type: Peptide

            Partner/Sponsor/Collaborator: CalRx Biosimilar Insulin Initiative

            Deal Size: $50.0 million Upfront Cash: Undisclosed

            Deal Type: Partnership March 18, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Through the acquisition, Eton will expand its portfolio with ET-600 which is an innovative product candidate under development for the treatment of an endocrinology condition.

            Lead Product(s): ET-600

            Therapeutic Area: Endocrinology Product Name: ET-600

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Eton Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition March 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Civica plans to produce three insulin biosimilars – glargine, lispro and aspart – each of which will be available both in vials and prefilled pens, and to ensure redundancy of supply, Ypsomed will provide injector dosing pens from their manufacturing facilities.

            Lead Product(s): Insulin Glargine

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Peptide

            Partner/Sponsor/Collaborator: Civica Rx

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership January 31, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe.

            Lead Product(s): Liraglutide

            Therapeutic Area: Endocrinology Product Name: Liraglutide-Generic

            Highest Development Status: Undisclosed Product Type: Peptide

            Partner/Sponsor/Collaborator: Zentiva

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 23, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            This collaboration has resulted in several high-impact scientific publications describing breakthrough inventions, including the SOMA robotic pill, which has subsequently been licensed exclusively to Novo Nordisk for clinical development.

            Lead Product(s): Biologic Medicine

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Massachusetts Institute of Technology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 09, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY